NCT01619774View on ClinicalTrials.gov

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Melanoma
Interventions
DRUG

GSK2118436

Starting dose 150 mg by mouth twice a day.

DRUG

GSK1120212

2 mg by mouth daily.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Cancer Prevention Research Institute of Texas

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01619774 - An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | Biotech Hunter | Biotech Hunter